重药控股 (000950.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

30.5x

Market Cap

CNY 9.27B

MomentumView details →

1D Return

−1.28%

YTD Return

−8.59%

RSI (14)

43.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

30.5x

Market Cap

CNY 9.27B

RSI (14)

43.6

MomentumView details →

1D Return

−1.28%

YTD Return

−8.59%

ProfitabilityView details →

Gross Margin

7.12%

Net Margin

0.53%

EBITDA Margin

1.24%

ROE (TTM)

3.69%

ROA (TTM)

0.63%

Asset Turnover

1.22x

GrowthView details →

Revenue YoY

+0.88%

EPS YoY

+41.60%

FCF YoY

—

Revenue CAGR 3Y

+6.72%

EPS CAGR 3Y

−26.32%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.05

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

1.86x

Current Ratio

1.20x

Quick Ratio

1.00x

Div Yield

1.13%

Div Rate

CNY 0.06

Div Growth 1Y

+100.00%

Financials snapshotView financials →

Revenue (TTM)

82.27B

Net Income (TTM)

432.21M

Op. CF (TTM)

−396.97M

Latest newsMore news →

Chongqing Pharmaceutical Holding Co., Ltd. announced its first-half 2026 results: net profit attributable to shareholders was 254 million yuan, down 9.85% year-on-year, with revenue of 40.132 billion yuan, down 2.57%.10d ago

Chongqing Pharmaceutical Holdings and its controlling subsidiaries have newly disclosed litigation and arbitration matters not previously disclosed within the past twelve months, with a total involved amount of 1.289 billion yuan, accounting for 11.17% of the company's most recent audited net assets attributable to the parent company.32d ago

Similar companies

泰恩康301263.SZ 步步高002251.SZ 雅创电子301099.SZ 建发致新301584.SZ 友阿股份002277.SZ 赛维时代301381.SZ Find similar companies →

Latest newsMore news →

Chongqing Pharmaceutical Holding Co., Ltd. announced its first-half 2026 results: net profit attributable to shareholders was 254 million yuan, down 9.85% year-on-year, with revenue of 40.132 billion yuan, down 2.57%.10d ago Chongqing Pharmaceutical Holdings and its controlling subsidiaries have newly disclosed litigation and arbitration matters not previously disclosed within the past twelve months, with a total involved amount of 1.289 billion yuan, accounting for 11.17% of the company's most recent audited net assets attributable to the parent company.32d ago